The back-to-AYUSH wave
Express Pharma|October 2020
The COVID-19 pandemic has seen increased interest in traditional remedies to build up personal immunity and nutrition.With India’s AYUSH ministry approving clinical studies and the WHO backing protocols for testing African herbal medicine, and most lately, the Health Minister releasing an Ayurveda and yoga-based national clinical management protocol for prevention and treatment of patients who are asymptomatic or have mild symptoms, will the COVID-19 pandemic finally bring respectability to a sector long scoffed at for being more faith than evidence-based? A review of the strategies at play, as new players plan to ride the immunity and nutrition wave, while legacy players move to the next level
Viveka Roychowdhury
The back-to-AYUSH wave

On September 20, theWorld Health Organisation endorsed a protocol for testing African herbal medicine as potential treatments for the coronavirus which causes COVID-19 as well as other epidemics. While India's AYUSH ministry must be feeling vindicated that they had approved clinical research studies on four Ayurvedic formulations way back on May 22, it is important to note that the WHO stressed that phase III clinical trials are pivotal in fully assessing the safety and efficacy of a new medical product.

The COVID-19 pandemic has seen an unprecedented interest in products with a ‘natural’ tag, as people try to undo years of unhealthy eating habits, lack of exercise and stressful work-life imbalances. While big FMCG companies such as Dabur reportedly clocked a 400 per cent surge in demand for Dabur Chyawanprash and an 80 per cent traction in Dabur Honey in the early months of the lockdown, the rising tide has lifted many newer companies and startups in the natural ingredients space. For instance, Mumbai-based OZiva reported a 40 per cent increase in queries especially in categories related to immunity and everyday fitness while Upakarma Ayurveda clocked a 35 per cent surge in the same categories.

But with so many brands crowding the natural space, and more joining in the gold rush triggered by the COVID-19 pandemic, how are both newbies and established brands standing out? Or will some brands lose out in the stampede? And how can they take on the cost versus benefits argument, especially when they seem to lack hard evidence and data that they are actually beneficial to users as they have not gone through the same regulatory approval process as prescription medicines? Here are some strategies at play.

Getting evidence on their side

この記事は Express Pharma の October 2020 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

この記事は Express Pharma の October 2020 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

EXPRESS PHARMAのその他の記事すべて表示
ACG covers every facet of the pharma process, all under one roof and seamlessly interconnected
Express Pharma

ACG covers every facet of the pharma process, all under one roof and seamlessly interconnected

ACG Inspection's Life Sciences Cloud will be making its India debut at the CPhI India- PMec India 2024 show. Udit Singh, CEO, ACG Inspection spoke to Viveka Roychowdhury on its USPs, highlighting its modular nature, the zero cost of transition from existing systems, and the advantage of ACG's long term partnerships with global standard setting organisations like GS1 which allow its platforms to deliver regulatory compliance deliverables in advance

time-read
4 分  |
December 2024
We, at OmniActive, invest over 10 per cent of the total outlay into R&D
Express Pharma

We, at OmniActive, invest over 10 per cent of the total outlay into R&D

Sanjaya Mariwala, Executive Chairman and MD, OmniActive Health Technologies shares insights into the company's significant investments in R&D, advanced testing capabilities, and strategies for optimising bioactive ingredients. He also discusses the impact of regulatory changes, quality assurance, and consumer education in the evolving nutraceutical landscape, in an interview with Viveka Roychowdhury

time-read
3 分  |
December 2024
Save coating time, boost production efficiency
Express Pharma

Save coating time, boost production efficiency

Instacoat 4G unique formulation includes an optimal ratio of polymer, plasticizer, and pigments, ensuring a smooth, uniform coating while significantly reducing preparation and process time

time-read
3 分  |
December 2024
Pharma companies can optimise R&D budgets using advanced technologies
Express Pharma

Pharma companies can optimise R&D budgets using advanced technologies

Pharma companies can optimise their R&D budgets to maximise innovation and deliver high-value therapies by using combination of new technologies to enhance innovation, feed the drug-development pipeline and speed to market.

time-read
1 min  |
December 2024
The wide-ranging health benefits of Pycnogenol for women of all ages
Express Pharma

The wide-ranging health benefits of Pycnogenol for women of all ages

Dr Franziska Weichmann, Manager of Scientific Communications and Product Development at Horphag Research, highlights benefits of Pycnogenol, a French maritime pine bark extract, offering women across all life stages a natural way to manage the physical and emotional challenges tied to hormonal changes

time-read
10+ 分  |
December 2024
Indian pharma industry: Urgent need for action in the manufacturing sector
Express Pharma

Indian pharma industry: Urgent need for action in the manufacturing sector

Dr Ajay Babu Pazhayattil, President of cGMPWorld, offers invaluable insights from FDA Form 483 observations issued to Indian pharma facilities, shedding light on the industry's critical challenges today. His analysis provides immediate and practical plans to minimise regulatory compliance risks. These measures will help reinforce the Indian industry's commitment to supplying the much-needed lifesaving drug products for the regulated US market

time-read
10 分  |
December 2024
Nutraceutical M&As: How strategic mergers are shaping the health and wellness market
Express Pharma

Nutraceutical M&As: How strategic mergers are shaping the health and wellness market

The nutraceutical industry has seen a surge in M&A activity over the past three years as companies pursue strategic acquisitions to strengthen market positions, diversify offerings, and drive innovation. Sudhindran N, GM - Corporate Affairs, Nutrify Today explores key trends, motivations, notable deals, and future growth prospects shaping the industry

time-read
3 分  |
December 2024
Rising research costs, complex drug systems, stringent regulations, and global pressures pose major threats to pharma R&D
Express Pharma

Rising research costs, complex drug systems, stringent regulations, and global pressures pose major threats to pharma R&D

According to one of the published reports, the pharma industry invested about $83 billion in R&D in 2019, which is about 10 times the research and development (R&D) spent per year in the 1980s, after adjusting for the effects of inflation.

time-read
1 min  |
December 2024
Harnessing data analytics to propel drug discovery and development in 2025
Express Pharma

Harnessing data analytics to propel drug discovery and development in 2025

As the pharma landscape evolves, data analytics will be at the forefront of drug discovery and development, transforming traditional methods. By leveraging data-driven insights, companies can expedite R&D, optimise clinical trials, and personalise treatments, bringing life-saving therapies to market more efficiently, explains Biju Davis, SVP, Engineering, Model N

time-read
4 分  |
December 2024
Strengthening our presence within APAC through increased penetration is a key focus
Express Pharma

Strengthening our presence within APAC through increased penetration is a key focus

Aanchal Tomar, Executive Director, Asia Pacific, Lonza Capsules Health Ingredients speaks about Lonza Capsules Health Ingredients’ strategic growth, challenges, and sustainability initiatives in the APAC market, showcasing their innovative capsule solutions and health ingredients that cater to the region's diverse pharmaceutical and nutraceutical needs, in an interview with Express Pharma

time-read
4 分  |
December 2024